Navy Approves "StormBreaker" Smart Weapon for Super Hornet Fleet

The U.S. Navy has officially cleared Raytheon’s StormBreaker smart weapon for operational use on F/A-18-E/F Super Hornet strike fighters. This advanced weapon is designed to hit moving and stationary targets even in poor weather conditions. Its compact size allows aircraft to carry more munitions, increasing the number of targets a single flight can engage.

Military officials stated that the integration of this technology significantly increases the lethality and survivability of the fleet. By allowing aircrews to strike mobile targets from a distance, the weapon reduces the time pilots must spend in high-risk environments.

While the Super Hornet is the first Navy aircraft to carry the weapon, it is already being integrated into other platforms like the F-35. The move is part of a broader push by the Department of Defense to modernize its precision-strike capabilities in response to evolving global threats.

FDA Approves First All-Oral Treatment for Adult Leukemia

The U.S. Food and Drug Administration has granted approval for a new combination therapy intended for adults with previously untreated chronic lymphocytic leukemia (CLL). This milestone establishes the first and only all-oral, fixed-duration regimen for these patients, allowing them to manage their condition without the need for traditional intravenous treatments.

Medical experts are calling the approval a significant win for patient flexibility. Because the treatment is a "fixed-duration" regimen, patients have the potential to take time off from medication once their initial treatment goals are met, rather than remaining on drugs indefinitely.

The approval was based on successful results from late-stage clinical trials that showed a meaningful improvement in long-term disease management. Pharmaceutical leaders say this move expands the options available to providers and patients who are navigating complex decisions regarding cancer care.

JPMorgan Report Shows U.S. Businesses Bearing Brunt of Tariffs

New research from the JP Morgan Chase Institute suggests that midsize American businesses are feeling the strain of recent tariff policies. The study found that tariff payments by these firms have tripled over the past year, directly contradicting claims that the financial burden falls primarily on foreign exporters. Businesses employing a total of 48 million people are reportedly facing mounting cost pressures as a result.

In response to these costs, many companies have been forced to raise prices for consumers or trim their hiring plans to protect profit margins. Some firms are also attempting to shift their supply chains away from China toward other regions in Asia to avoid the heaviest duties.

The White House has dismissed the findings, maintaining that the administration's trade strategy is necessary for long-term economic growth. However, recent figures from the U.S. Census Bureau show the trade deficit widening, adding further fuel to the debate over the effectiveness of the current tariff landscape.